Dual antiplatelet therapy duration: what are the drivers?

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) is crucial post-percutaneous coronary intervention (PCI).
• Optimal DAPT duration remains a subject of debate and evolving research.
• Guidelines vary regarding DAPT duration based on stent type and clinical presentation.

Purpose of the Study:

• To review and synthesize current evidence on DAPT duration following PCI.
• To evaluate the discordance in existing guidelines for DAPT therapy.
• To assess the impact of stent type and patient characteristics on DAPT recommendations.

Main Methods:

• Systematic review of recent guidelines and clinical studies on DAPT duration.
• Comparative analysis of European and American guidelines for PCI.
• Evaluation of studies investigating stent thrombosis with different stent generations.

Main Results:

• European guidelines suggest 1 month post-bare metal stent (BMS), 6-12 months post-drug-eluting stent (DES) for stable angina, and 1 year post-acute coronary syndrome (ACS).
• American guidelines (2011) recommend 12 months DAPT for ACS regardless of stent type.
• Newer generation DES show reduced late stent thrombosis compared to older generations, but evidence for prolonged DAPT benefit is not clearly demonstrated.

Conclusions:

• Current guidelines present discordant recommendations, often prioritizing device type over patient clinical factors.
• The clinical benefit of extending DAPT duration beyond standard periods is not definitively established.
• Further research is needed to personalize DAPT duration based on individual patient risk profiles and clinical outcomes.